Search

everythinglearnresearchcommunity

for

Search:↓

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user shared their 3-month progress using topical minoxidil 6% twice daily and finasteride 1mg six days a week, along with a hair and scalp treatment. They reported no side effects and plan to add a dermastamp to their routine.

A 23-year-old male is using finasteride (1mg daily), derma rolling, and Nizoral for hair loss treatment, experiencing increased shedding and side effects like anxiety, decreased libido, and fatigue. Despite no positive changes in hair after three months, he plans to continue finasteride and may consider RU58841 or CB as future treatments, avoiding minoxidil due to past negative experiences.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation discusses hair regrowth progress using 1mg oral finasteride and 5mg oral minoxidil daily over three years. Concerns about potential heart risks from minoxidil dosage are raised, with suggestions to consult a doctor and consider reducing the dose.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

A thirty year old's progress with hair loss treatment, which includes finasteride, minoxidil and dermarolling in addition to taking multivitamins with biotin. The user has seen improvement after three months of using this regimen.

The conversation is about a person's hair regrowth after 100 days using finasteride (0.5mg), minoxidil (3mg), and dermarolling, with others noticing improvement and discussing the appearance of the scalp and hairline.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Using dutasteride 0.5mg three times a week may be more effective than daily finasteride for hair regrowth, but experiences vary, with some users reporting side effects like anxiety and mood swings. Others suggest combining finasteride with dutasteride initially, while some find topical minoxidil more tolerable.

The user shared an update on their hair loss treatment, showing progress after three months of using 1mg finasteride daily. The first three pictures are before starting finasteride, and the last three show the results after three months.

The conversation discusses experimenting with microneedling for hair loss, with OP considering using a 3mm derma-stamp. Other users advise against going beyond 1.5mm to avoid damage.

User shared progress pictures after 3 months of using topical finasteride, topical minoxidil, dermastamp, and Nizoral. They applied finasteride and minoxidil daily, used dermastamp weekly, and Nizoral every other day.

The user shared progress pictures after using a topical treatment of 0.3% finasteride and 6% minoxidil once a day for a year, noting improvement in the front but needing suggestions for the crown. They confirmed using a product from Hims.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The user experienced heart palpitations from using Fin (0.1%) and Min (10%) and is seeking alternatives. Options suggested include PRP or Mesotherapy, with a recommendation to try topical Fin without Min.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The user has been using minoxidil foam and a dermaroller for three months to combat hair loss, with noticeable progress. They are seeking finasteride but face difficulties obtaining it in Germany.

A 31-year-old experienced significant hair regrowth using Minoxidil 5% topical twice daily and Finasteride 0.625mg daily, with additional microneedling. The user reported initial shedding, improved hair thickness, and no major side effects, impressing their dermatologist with the results.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.